Reason for request
Renewal of inclusion
Clinical Benefit
| Substantial |
The actual benefit of DOTAREM remains substantial. |
Clinical Added Value
| minor |
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification. |
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
Wz83z9KuYCgPb7LU
